One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R.TeerlinkMDaRafaelDiazMDbG. MichaelFelkerMD, MHScJohn J.V.McMurrayMDdMarcoMetraMDeScott D.SolomonMDfTorBiering-S?rensenMD, PhD, MPHgMichaelB?hmMDhDianaBondermanMDiJames C.FangMDjDavid E.LanfearMDkMayannaLundMDlShin-ichiMomomuraMDmEileenO'MearaMDnPiotrPonikowskiMD, PhDoJindrichSpinarMD, PhDpJose H.Flores-ArredondoMDqBrian L.ClaggettPhDfStephen B.HeitnerMDrStuartKupferMDrSiddique A.AbbasiMDqFady I.MalikMD, PhDron behalf of theGALACTIC-HF Investigators
doi : 10.1016/j.jacc.2021.04.065
Volume 78, Issue 2, 13 July 2021, Pages 97-108
In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint (PCE) of time-to-first heart failure event or cardiovascular death in patients with heart failure and reduced ejection fraction (EF) (?35%).
Omecamtiv Mecarbil: A Personalized Treatment for Patients With Severely Impaired Ejection Fraction?
Jo?o PedroFerreiraMD, PhD
doi : 10.1016/j.jacc.2021.04.077
Volume 78, Issue 2, 13 July 2021, Pages 109-111
Transesophageal Echocardiography in Patients Undergoing Coronary Artery Bypass Graft Surgery
Thomas S.MetkusMDaDylanThibaultMSbMichael C.GrantMDcVinayBadhwarMDdJeffrey P.JacobsMDeJenniferLawtonMDfSean M.O'BrienPhDbVinodThouraniMDgZachary K.WegermannMDhBrittanyZwischenbergerMDiRobertHigginsMDe
doi : 10.1016/j.jacc.2021.04.064
Volume 78, Issue 2, 13 July 2021, Pages 112-122
The impact of utilization of intraoperative transesophageal echocardiography (TEE) at the time of isolated coronary artery bypass grafting (CABG) on clinical decision making and associated outcomes is not well understood.
Improving CABG Mortality Further: Striving Toward Perfection?
AbrahamSonnyMDabcLeeJosephMD, MSde
doi : 10.1016/j.jacc.2021.05.009
Volume 78, Issue 2, 13 July 2021, Pages 123-125
Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities
Kevin L.ThomasMDaHussein R.Al-KhalidiPhDaAdam P.SilversteinMSaKristi H.MonahanRNbTristram D.BahnsonMDaJeanne E.PooleMDcDaniel B.MarkMD, MPHaDouglas L.PackerMDbCABANA Investigators
doi : 10.1016/j.jacc.2021.04.092
Volume 78, Issue 2, 13 July 2021, Pages 126-138
Rhythm control strategies for atrial fibrillation (AF), including catheter ablation, are substantially underused in racial/ethnic minorities in North America.
Catheter Ablation Is Better Than Drugs for Treatment of AF in Racial and Ethnic Minorities?
Andrea M.RussoMD
doi : 10.1016/j.jacc.2021.05.008
Volume 78, Issue 2, 13 July 2021, Pages 139-141
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
GerasimosFilippatosMDaGeorge L.BakrisMDbBertramPittMDcRajivAgarwalMD, MSdPeterRossingMDefLuis M.RuilopeMDghiJavedButlerMDjCarolyn S.P.LamMBBS, PhDkPeterKolkhofPhDlLukeRobertsMBBS, PhDmChristophTastoPhDnAmerJosephMBBSoStefan D.AnkerMDpFIDELIO-DKD Investigators
doi : 10.1016/j.jacc.2021.04.079
Volume 78, Issue 2, 13 July 2021, Pages 142-152
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models.
Do Mineralocorticoid Receptor Antagonists Suppress Atrial Fibrillation/Flutter??
Gerald V.NaccarelliMDaEdward J.FilipponeMDbAndrewFoyMDa
doi : 10.1016/j.jacc.2021.04.080
Volume 78, Issue 2, 13 July 2021, Pages 153-155
no abstract
Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8
BorjaIbanezMD, PhDabc?AntonioFern?ndez-OrtizMD, PhDacd?LeticiaFern?ndez-FrieraMD, PhDaceInésGarc?a-LunarMD, PhDacfVicenteAndrésPhDacValent?nFusterMD, PhDag
doi : 10.1016/j.jacc.2021.05.011
Volume 78, Issue 2, 13 July 2021, Pages 156-179
Atherosclerosis starts early in life and progresses silently for decades. Considering atherosclerosis as a “systemic disease” invites the use of noninvasive methodologies to detect disease in various regions before symptoms appear. The PESA-(Progression of Early Subclinical Atherosclerosis) CNIC-SANTANDER study is an ongoing prospective cohort study examining imaging, biological, and behavioral parameters associated with the presence and progression of early subclinical atherosclerosis. Between 2010 and 2014, PESA enrolled 4,184 asymptomatic middle-aged participants who undergo serial 3-yearly follow-up examinations including clinical interviews, lifestyle questionnaires, sampling, and noninvasive imaging assessment of multiterritorial subclinical atherosclerosis (carotids, iliofemorals, aorta, and coronaries). PESA tracks the trajectories of atherosclerosis and associated disorders from early stages to the transition to symptomatic phases. A joint venture between the CNIC and the Santander Bank, PESA is expected to run until at least 2029, and its significant contributions to date are presented in this review paper.
Improving Terminology to Describe Coronary Artery Procedures: JACC Review Topic of the Week
TorstenDoenstMD, PhDaRobert O.BonowMD, PhDbDeepak L.BhattMD, MPHcVolkmarFalkMD, PhDdMarioGaudinoMD, PhDe
doi : 10.1016/j.jacc.2021.05.010
Volume 78, Issue 2, 13 July 2021, Pages 180-188
Coronary artery disease (CAD) is treated with medical therapy with or without percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The latter 2 options are commonly referred to as “myocardial revascularization” procedures. We reason that this term is inappropriate because it is suggestive of a single treatment effect of PCI and CABG (ie, the reestablishment of blood flow to ischemic myocardium) and obscures key mechanisms, such as the improvement in coronary flow capability in the absence of ongoing ischemia, the reperfusion in the presence of ischemia, and the prevention of myocardial infarction from CAD progression. We review the current evidence on the topic and suggest the use of a purely descriptive terminology (“invasive treatment by PCI or CABG”) which has the potential to improve clinical decision making and guide future trial design.
Is it Time for Sex-Specific Guidelines for Cardiovascular Disease?
Ersilia M.DeFilippisMDaHarriette G.C.Van SpallMD, MPHbcd
doi : 10.1016/j.jacc.2021.05.012
Volume 78, Issue 2, 13 July 2021, Pages 189-192
Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
ZahidAhmadMDRobertPordyMDDaniel J.RaderMDDanielGaudetMD, PhDShaziaAliPharmDClaudiaGonzaga-JaureguiPhDManish P.PondaMD, MSBradShumelMDPoulabiBanerjeePhDRichard L.DunbarMD
doi : 10.1016/j.jacc.2021.04.091
Volume 78, Issue 2, 13 July 2021, Pages 193-195
Race/Ethnicity and Prevalence of Aortic Stenosis by Echocardiography in the Multi-Ethnic Study of Atherosclerosis
Matthew J.CzarnyMDSanjiv J.ShahMDSeamus P.WheltonMD, MPHMichael J.BlahaMD, MPHMichael Y.TsaiPhDRimskyDenisMD, MPH, MBAAlainBertoniMD, MPHWendy S.PostMD, MS
doi : 10.1016/j.jacc.2021.04.078
Volume 78, Issue 2, 13 July 2021, Pages 195-197
Carotid Intraplaque Hemorrhage and Cardiovascular Events: Are Antithrombotic Therapies the Missing Piece of the Puzzle?
VictorAboyansMD, PhDLucieChastaingtMDJulienMagnePhDPhilippeLacroixMD
doi : 10.1016/j.jacc.2021.03.343
Volume 78, Issue 2, 13 July 2021, Pages 197-198
Reply: Carotid Intraplaque Hemorrhage and Cardiovascular Events: Are Antithrombotic Therapies the Missing Piece of the Puzzle?
DanielBosMD, PhDMeike W.VernooijMD, PhDMaryamKavousiMD, PhDAadvan der LugtMD, PhD
doi : 10.1016/j.jacc.2021.04.081
Volume 78, Issue 2, 13 July 2021, Pages 198-200
